1. Home
  2. CGON vs NATL Comparison

CGON vs NATL Comparison

Compare CGON & NATL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGON
  • NATL
  • Stock Information
  • Founded
  • CGON 2010
  • NATL 2023
  • Country
  • CGON United States
  • NATL United States
  • Employees
  • CGON N/A
  • NATL N/A
  • Industry
  • CGON
  • NATL
  • Sector
  • CGON
  • NATL
  • Exchange
  • CGON NYSE
  • NATL Nasdaq
  • Market Cap
  • CGON 2.0B
  • NATL 2.2B
  • IPO Year
  • CGON 2024
  • NATL N/A
  • Fundamental
  • Price
  • CGON $26.91
  • NATL $26.97
  • Analyst Decision
  • CGON Strong Buy
  • NATL Buy
  • Analyst Count
  • CGON 11
  • NATL 4
  • Target Price
  • CGON $63.30
  • NATL $38.75
  • AVG Volume (30 Days)
  • CGON 979.0K
  • NATL 817.6K
  • Earning Date
  • CGON 08-07-2025
  • NATL 08-06-2025
  • Dividend Yield
  • CGON N/A
  • NATL N/A
  • EPS Growth
  • CGON N/A
  • NATL N/A
  • EPS
  • CGON N/A
  • NATL 1.55
  • Revenue
  • CGON $662,000.00
  • NATL $4,247,000,000.00
  • Revenue This Year
  • CGON N/A
  • NATL $1.81
  • Revenue Next Year
  • CGON $21,843.29
  • NATL $4.46
  • P/E Ratio
  • CGON N/A
  • NATL $17.47
  • Revenue Growth
  • CGON 224.51
  • NATL N/A
  • 52 Week Low
  • CGON $14.80
  • NATL $22.30
  • 52 Week High
  • CGON $40.47
  • NATL $35.50
  • Technical
  • Relative Strength Index (RSI)
  • CGON 54.12
  • NATL 44.39
  • Support Level
  • CGON $25.14
  • NATL $23.56
  • Resistance Level
  • CGON $27.09
  • NATL $28.13
  • Average True Range (ATR)
  • CGON 1.50
  • NATL 1.34
  • MACD
  • CGON -0.04
  • NATL -0.16
  • Stochastic Oscillator
  • CGON 53.56
  • NATL 51.43

About CGON CG ONCOLOGY INC

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

About NATL NCR Atleos Corporation

NCR Atleos Corp is financial technology company providing self-directed banking solutions to a customer base including financial institutions, merchants, manufacturers, retailers and consumers. Self-directed banking is a rapidly growing, secular trend that allows banking customers to transact seamlessly between various channels all for the same transaction. Their comprehensive solutions enable the acceleration of self-directed banking through ATM and interactive teller machine (ITM) technology, including software, services, hardware and its proprietary Allpoint network. Atleos manage its operations in the following segments which includes Self-Service Banking, Network, and Telecommunications abd Technology.

Share on Social Networks: